All eyes on Amsterdam

Article

"Recognising the trend amongst European ophthalmologists to sub-specialise has been a high priority for the European Society of Ophthalmology," its president Gabriel van Rij told Ophthalmology Times Europe.

"Recognising the trend amongst European ophthalmologists to sub-specialise has been a high priority for the European Society of Ophthalmology," its president Gabriel van Rij told Ophthalmology Times Europe. With over different 72 sessions during its 17th congress in June this year the Societas Ophthalmologica Europaea (SOE) potentially has something to offer every European doctor.

The SOE, which was established in 1956, invites all the major sub-speciality societies to take part in the preparation of its Congress, which, in turn, provides delegates with an event where they can meet and learn from leaders in each branch of ophthalmology.

"Our overall mission," explains Dr van Rij, "is of course to promote ophthalmology in Europe and to stimulate co-operation between European ophthalmologists and their National Societies. However, the world has changed since 1956 and so have we - fostering collaboration with all sub-speciality societies and supranational organisations with Europe and even beyond is now key."

The scientific programme of course includes cataract & refractive, retina, glaucoma and cornea but delegates interested in oncology & pathology, oculoplastics, paediatrics and strabismus, education, women in ophthalmology, neuro-ophthalmology, uveitis, electrophysiology or ocular trauma will not miss out. To see the symposia programme in full detail click here.

The congress is English speaking and takes place every two years. This year's event is in Amsterdam. "We are conscious of the variation in resources available across Europe, especially in today's economic climate," continued van Rij. "Subsequently, we provide reduced congress registration fees for most Eastern European delegates and each year we offer 70 educational travel grants for east-European ophthalmologists-in-training. These help young doctors not just financially but open doors to sub-specialist departments in all the major European centres."

"Another SOE innovation last year was the Young Ophthalmologist Programme open to residents and young specialists up to five years after board certification. The programme consists of an open forum for exchange of ideas and information about training, advice on observerships, fellowships and career building. Led sessions will be organised at major conferences and social events."

Getting a level playing field in education across Europe is a key challenge according to Dr van Rij: "There are countries where you can be an ophthalmologist in one year and countries where you need at least five years training. That presents many issues and challenges."

For more details go to www.soe2009.org

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.